Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Esperion Therapeutics Inc (NASDAQ: ESPR) was $2.66 for the day, down -3.27% from the previous closing price of $2.75. In other words, the price has decreased by -$3.27 from its previous closing price. On the day, 10.69 million shares were traded. ESPR stock price reached its highest trading level at $2.9399 during the session, while it also had its lowest trading level at $2.65.
Ratios:
Our analysis of ESPR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 1.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on December 18, 2024, initiated with a Neutral rating and assigned the stock a target price of $4.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8.
BofA Securities Downgraded its Neutral to Underperform on June 20, 2024, while the target price for the stock was maintained at $2.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 17 ’25 when Looker Benjamin sold 6,267 shares for $2.80 per share. The transaction valued at 17,573 led to the insider holds 393,670 shares of the business.
Koenig Sheldon L. sold 28,427 shares of ESPR for $79,254 on Sep 17 ’25. The President and CEO now owns 1,518,831 shares after completing the transaction at $2.79 per share. On Sep 17 ’25, another insider, Halladay Benjamin, who serves as the Chief Financial Officer of the company, sold 7,046 shares for $2.81 each. As a result, the insider received 19,785 and left with 474,862 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 536316736 and an Enterprise Value of 1048433728. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.00. Its current Enterprise Value per Revenue stands at 3.91 whereas that against EBITDA is -29.666.
Stock Price History:
The Beta on a monthly basis for ESPR is 0.96, which has changed by 0.63190186 over the last 52 weeks, in comparison to a change of 0.1653893 over the same period for the S&P500. Over the past 52 weeks, ESPR has reached a high of $3.94, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is 36.01%, while the 200-Day Moving Average is calculated to be 59.05%.
Shares Statistics:
ESPR traded an average of 5.27M shares per day over the past three months and 6838080 shares per day over the past ten days. A total of 200.16M shares are outstanding, with a floating share count of 196.99M. Insiders hold about 2.31% of the company’s shares, while institutions hold 48.89% stake in the company. Shares short for ESPR as of 1756425600 were 22348965 with a Short Ratio of 4.24, compared to 1753920000 on 23127867. Therefore, it implies a Short% of Shares Outstanding of 22348965 and a Short% of Float of 11.129999999999999.
Earnings Estimates
The market rating of Esperion Therapeutics Inc (ESPR) is currently shaped by the ongoing analysis conducted by 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.24, with high estimates of $0.62 and low estimates of -$0.11.
Analysts are recommending an EPS of between $0.36 and -$0.48 for the fiscal current year, implying an average EPS of -$0.02. EPS for the following year is -$0.04, with 6.0 analysts recommending between $0.35 and -$0.28.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $96.7M to a low estimate of $58.7M. As of. The current estimate, Esperion Therapeutics Inc’s year-ago sales were $51.63MFor the next quarter, 7 analysts are estimating revenue of $146.69M. There is a high estimate of $210.2M for the next quarter, whereas the lowest estimate is $65.3M.
A total of 8 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $439.4M, while the lowest revenue estimate was $236.52M, resulting in an average revenue estimate of $367.2M. In the same quarter a year ago, actual revenue was $332.31MBased on 8 analysts’ estimates, the company’s revenue will be $341.59M in the next fiscal year. The high estimate is $396.8M and the low estimate is $263.6M.
